David Miklos, MD, PhD, discusses the latest findings at the ASH 2017 meeting in Atlanta.
Ibrutinib for Graft Versus Host Disease

David Miklos, MD, PhD, discusses the latest findings at the ASH 2017 meeting in Atlanta.
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.